Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management
- PMID: 28629235
- DOI: 10.1080/10428194.2017.1339874
Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management
Abstract
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor finding increasingly widespread use in non-Hodgkin lymphoma. Evidence of an increased risk of atrial fibrillation (AF) emerged in Phase III studies with a median incidence of approximately 6%. The mechanism remains unknown, but inhibition of a cardioprotective pathway has been proposed. Ibrutinib induces a platelet function defect, increasing the bleeding risk of anticoagulation for AF stroke prophylaxis. Multiple potential drug interactions are an added complication. In this review we examine the characteristics and management of the reported cases of AF with ibrutinib and where possible make recommendations. The evidence suggests dose reduction or temporary suspension of drug, are feasible alternative to discontinuation. The optimum choice of thromboprophylaxis has not been determined, but we propose the use of novel anticoagulants (NOACs) and avoidance of anti-platelet agents where possible. Further research and consensus guidelines are required.
Keywords: Atrial fibrillation; Waldenstrom macroglobulinemia; anti-coagulation; chronic lymphocytic leukemia; ibrutinib; mantle cell lymphoma.
Similar articles
-
Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.Br J Haematol. 2016 Nov;175(3):462-466. doi: 10.1111/bjh.14324. Epub 2016 Sep 9. Br J Haematol. 2016. PMID: 27611233
-
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.Haematologica. 2017 Oct;102(10):1796-1805. doi: 10.3324/haematol.2017.171041. Epub 2017 Jul 27. Haematologica. 2017. PMID: 28751558 Free PMC article.
-
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.Leuk Lymphoma. 2018 Jul;59(7):1554-1564. doi: 10.1080/10428194.2017.1375110. Epub 2017 Sep 13. Leuk Lymphoma. 2018. PMID: 28901789 Review.
-
Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.Leuk Lymphoma. 2017 Dec;58(12):2811-2814. doi: 10.1080/10428194.2017.1315115. Epub 2017 May 15. Leuk Lymphoma. 2017. PMID: 28504030 Review.
-
Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.Drugs Aging. 2017 Jul;34(7):509-527. doi: 10.1007/s40266-017-0468-4. Drugs Aging. 2017. PMID: 28536906 Review.
Cited by
-
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.PLoS One. 2019 Feb 20;14(2):e0211228. doi: 10.1371/journal.pone.0211228. eCollection 2019. PLoS One. 2019. PMID: 30785921 Free PMC article.
-
Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.Ann Pharmacother. 2020 Sep;54(9):879-898. doi: 10.1177/1060028020909117. Epub 2020 Feb 20. Ann Pharmacother. 2020. PMID: 32079411 Free PMC article. Review.
-
Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents.Cancers (Basel). 2024 May 24;16(11):1996. doi: 10.3390/cancers16111996. Cancers (Basel). 2024. PMID: 38893115 Free PMC article. Review.
-
The risk vs. benefit calculus of anticoagulation in patients with ibrutinib-related atrial fibrillation.Leuk Lymphoma. 2024 Feb;65(2):168-174. doi: 10.1080/10428194.2023.2278433. Epub 2024 Jan 24. Leuk Lymphoma. 2024. PMID: 37953609 Free PMC article.
-
Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function.Am J Physiol Cell Physiol. 2021 May 1;320(5):C902-C915. doi: 10.1152/ajpcell.00296.2020. Epub 2021 Mar 10. Am J Physiol Cell Physiol. 2021. PMID: 33689480 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
